EP0471612B1 - Nouveaux 19-Nor stéroides ayant en position 11béta une chaíne carbonée comportant une fonction amide, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant - Google Patents

Nouveaux 19-Nor stéroides ayant en position 11béta une chaíne carbonée comportant une fonction amide, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant Download PDF

Info

Publication number
EP0471612B1
EP0471612B1 EP91402214A EP91402214A EP0471612B1 EP 0471612 B1 EP0471612 B1 EP 0471612B1 EP 91402214 A EP91402214 A EP 91402214A EP 91402214 A EP91402214 A EP 91402214A EP 0471612 B1 EP0471612 B1 EP 0471612B1
Authority
EP
European Patent Office
Prior art keywords
radical
formula
product
agent
subjected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91402214A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0471612A3 (en
EP0471612A2 (fr
Inventor
André Claussner
François Nique
Jean-Georges Teutsch
Patrick Van De Velde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9010323A external-priority patent/FR2665901B2/fr
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of EP0471612A2 publication Critical patent/EP0471612A2/fr
Publication of EP0471612A3 publication Critical patent/EP0471612A3/fr
Application granted granted Critical
Publication of EP0471612B1 publication Critical patent/EP0471612B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Definitions

  • the present invention relates to novel 19-Nor steroids having in libéta a carbon chain comprising a function amide or thioamide, process for their preparation and intermediates of this process, their application as drugs and the new pharmaceutical compositions the containing.
  • European patent application EP 0308345 describes steroids with a spirannic cycle in position 17 and the European patent application EP 0384842 describes 19-norsteroids having in 11beta a carbon chain comprising an amide or carbamate function.
  • R 17 is an acyloxy radical, it may especially be the derivative of a saturated or unsaturated aliphatic or cycloaliphatic acid and in particular of an alkanoic acid such as for example acetic, propionic, butyric or isobutyric, valeric or undecylic acid.
  • a hydroxyalkanoic acid such as for example hydroxyacetic acid
  • a cycloalkylcarboxylic acid or (cycloalkyl) alkanoic acid such as for example cyclopropyl, cyclopentyl or cyclohexylcarboxylic acid, cyclopentyl or cyclohexyl acetic or propionic acid
  • a benzoic acid a salicylic acid or a phenylalkanoic acid such as l phenetic acetic or phenyl propionic acid, an amino acid such as diethylamino acetic or aspartic acid or formic acid. It is preferably the derivative of acetic, propionic, butyric or butanedioic acid.
  • R ′ 17 represents an alkyl radical, it may be the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, n-pentyl, n-hexyl, 2-methyl pentyl, 2,3-dimethyl butyl, n- radical. heptyl, 2-methylexyl, 2,2-dimethylpentyl, 3,3-dimethyl pentyl, 3-ethylpentyl, n-octyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 3-methyl 3-ethylpentyl.
  • R ′ 17 represents an alkenyl radical, it may be a vinyl, propenyl, isopropenyl, allyl, 2-methylallyl, butenyl or isobutenyl radical. It is preferably the vinyl or propenyl radical.
  • R ′ 17 represents an alkynyl radical, it may be the ethynyl, propynyl, propargyl, butynyl or isobutynyl radical. It is preferably the ethynyl or propynyl radical.
  • X represents an arylene group, it is preferably the phenylene radical.
  • X represents an arylenoxy group, it is preferably the phenylenoxy radical.
  • X represents an arylenethio radical, it is preferably the phenylenethio radical.
  • Y represents a linear aliphatic chain or branched, saturated or unsaturated, it can be the radical methylene, ethylene, propylene, isopropylene, butylene, isobutylene, or tert-butylene, n-pentylene, n-hexylene, 2-methyl pentylene, 2,3-dimethyl butylene, n-heptylene, 2-methylhexylene, 2,2-dimethylpentylene, 3,3-dimethylpentylene, 3-ethylpentylene, n-octylene, 2,2-dimethylhexylene, 3,3-dimethylhexylene, 3-methyl 3-ethylpentylene, nonylene, 2,4-dimethyl heptylene, n-decylene, n-undecylene, n-dodecylene, n-tridecylene, n-tetradecylene, n-penta dec
  • It can also be vinylene radicals, isopropenylene, allylene, 2-methylallylene or isobutenylene, and when the chain is interrupted or terminated by one or several arylen radicals, it is preferably the radical phenylene, it being understood that finished concerns one any of the two ends of Y.
  • RA or RA′ represents an alkyl radical
  • it can be the methyl, ethyl, propyl, isopropyl radical, butyl, isobutyl or tert-butyl, n-pentyl, n-hexyl, 2-methyl pentyl, 2,3-dimethyl butyl, n-heptyl, 2-methylhexyl, 2,2-dimethylpentyle, 3,3-dimethyl pentyle, 3-ethylpentyle, n-octyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 3-methyl 3-ethylpentyle.
  • radicals can be substituted by one or several aryl radicals such as phenyl, furyl, thienyl, preferably a phenyl radical, by one or more radicals alkylamino or dialkylamino such as dimethylamino or by one or several carboxyls esterified for example by a methoxycarbonyl or an ethoxycarbonyl, by one or more atoms halogen, for example fluorine, chlorine or bromine.
  • aryl radicals such as phenyl, furyl, thienyl, preferably a phenyl radical
  • radicals alkylamino or dialkylamino such as dimethylamino or by one or several carboxyls esterified for example by a methoxycarbonyl or an ethoxycarbonyl
  • atoms halogen for example fluorine, chlorine or bromine.
  • RA and RA ′ form with the nitrogen atom to which they are linked a heterocycle with 5 or 6 links, it is a saturated heterocycle, preferably a pyrrolidine or a piperidine optionally substituted by an alkyl radical such than methyl, ethyl, propyl or isopropyl, preferably methyl or ethyl, by an aryl radical such as phenyl or tolyl or with an alkylaryl radical such as benzyl or phenylethyl, preferably benzyl or an unsaturated heterocycle, preferably an optionally substituted pyrrole or pyridine by an alkyl radical such as methyl, optionally containing another heteroatom, preferably a morpholine, a piperazine or a pyrimidine, optionally substituted by a alkyl radical, preferably methyl or ethyl.
  • an alkyl radical such than methyl, ethyl, propyl or isopropyl, preferably
  • the present application relates more particularly to the products of formula (I A ) for which n is equal to 1.
  • the compounds of formula (V) are obtained by making react a compound of formula (III) activated for example under form of mixed anhydride by action of an agent such as chloroformate, for example isobutyl chloroformate, in presence of a base such as a tertiary amine, for example N-methylmorpholine, in an anhydrous solvent such as chlorinated solvent, for example methylene chloride, with the amine of formula (IV).
  • an agent such as chloroformate, for example isobutyl chloroformate
  • a base such as a tertiary amine, for example N-methylmorpholine
  • an anhydrous solvent such as chlorinated solvent, for example methylene chloride
  • the product of formula (III) is obtained using an oxidizing agent such as, for example, the CrO 3 - sulfuric acid mixture in a neutral solvent such as, for example, acetone.
  • an oxidizing agent such as, for example, the CrO 3 - sulfuric acid mixture in a neutral solvent such as, for example, acetone.
  • the compounds of formula (II) comprise an 11beta chain terminated by an alcohol function chosen from the following table:
  • the compounds of formula (III) include a chain in 11beta, completed by a carboxylic function, corresponding to the oxidation product of a chain chosen from among the chains in 11beta finished by one of the alcohol functions mentioned above, the compound of formula (IV) is chosen from amines such as by example butylamine, methylbutylamine, methylisopropylamine or benzylpiperidine which are known products, or methyl hepta-fluorobutylamine the preparation of which is given below.
  • amines such as by example butylamine, methylbutylamine, methylisopropylamine or benzylpiperidine which are known products, or methyl hepta-fluorobutylamine the preparation of which is given below.
  • the compound of formula (V) has a hydroxy function in 17
  • the corresponding acyloxylated steroid in 17beta is obtained, by action of an acylating agent, for example acetylation such as acetic anhydride in pyridine, in possible presence of 4-dimethylaminopyridine.
  • an acylating agent for example acetylation such as acetic anhydride in pyridine
  • the compounds of formula (I) which are steroid derivatives estradiol having an 11beta chain comprising a substituted amide function are obtained from the compounds of formula (V) by action of a flavoring agent such as palladium hydroxide on magnesia in methanol or well the acetyl bromide-acetic anhydride mixture, at a temperature not exceeding room temperature, followed a controlled saponification reaction with, for example, potash in methanol, sodium bicarbonate or methanol in the presence of hydrochloric acid.
  • a flavoring agent such as palladium hydroxide on magnesia in methanol or well the acetyl bromide-acetic anhydride mixture
  • R A or R A ′ is a hydrogen atom
  • the corresponding alkylated product is obtained by the action of an alkyl halide, for example methyl or ethyl iodide, methyl bromide or ethyl in a solvent such as tetrahydrofuran.
  • R ′ 17 comprises an alkyl, alkenyl or alkynyl radical substituted by a reactive function, the latter can be temporarily protected by the usual methods.
  • the products of formula (I) in which Y represents a branched aliphatic chain can be prepared by alkylation of the products of formula (I) in which Y represents a linear aliphatic chain after having, the case if necessary, blocked the reactive functions at 3 and 17.
  • the alkylation is carried out for example using a halide alkyl such as methyl iodide, in the presence of lithium diisopropylamide.
  • K is an oxygen atom
  • a sulfurizing agent for example [2,4-bis (4-methyoxyphenyl) -1,3-dithia-2,4-diphosphenate-2,4-disulfide] (Lawesson reagent), after possible blocking of reactive functions in 3 and 17.
  • W represents an activated derivative of the radical mercapto
  • it can be a metal thiolate, for example money.
  • the compounds of formula (I) present interesting pharmacological properties.
  • the study of products on hormone receptors helped to highlight that they in particular have remarkable anti-estrogen activity and anti-proliferative properties, such as show the test results given below.
  • the subject of the invention is therefore the products of formula (I) as medication.
  • the useful dosage varies depending on the condition treat and route of administration; it can vary by example from 1 to 100 mg per day in adults orally.
  • the invention extends to pharmaceutical compositions containing at least one of the medicinal products as active ingredient as defined above.
  • the compounds of formula (I) are used digestively, parenteral or local, for example percutaneously. They can be prescribed as simple tablets or sugar-coated tablets, capsules, granules, suppositories, eggs, injections, ointments, creams, gels, microspheres, implants, patches, which are prepared according to the usual methods.
  • the active ingredient (s) may be incorporated therein excipients usually used in these compositions pharmaceuticals, such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous vehicles or not, original fatty substances animal or vegetable, paraffinic derivatives, glycols, various wetting, dispersing or emulsifying agents, conservatives.
  • excipients usually used in these compositions pharmaceuticals, such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous vehicles or not, original fatty substances animal or vegetable, paraffinic derivatives, glycols, various wetting, dispersing or emulsifying agents, conservatives.
  • the products of formula (VII) in which W is a mercapto radical, possibly activated are products new and the invention therefore also relates to the products of formula (VII) as defined above, in which W represents a mercapto radical possibly activated as new intermediate products.
  • Products new (VII) defined above can be prepared by action of a magnesian containing a mercapto group on a product of formula (XII). Specific examples of preparations of such new products (VII) are described below in the examples.
  • the compounds of formula (I) of the present application constitute for some of the compounds corresponding to the formula general above but not specifically described in this demand and for others related compounds.
  • Stage A 3 - [[dimethyl (1,1-dimethyl ethyl) silyl] oxy] propanol.
  • Stage B [(3-bromopropyl) oxy] -dimethyl- (1,1-dimethyl ethyl) silane.
  • Stage A 3- (1,2-Ethanediyl) cyclic acetal of 11beta- (4-hydroxyphenyl) 5-alpha-hydroxy estra-9-en 3,17-dione.
  • the crude product obtained above is dissolved in 150 cm 3 of tetrahydrofuran, 130 cm 3 of a 1M solution of tetrabutylammonium fluoride are added. The mixture is stirred for 15 minutes at room temperature, poured into water, extracted with ethyl acetate, washed with water, dried and evaporated to dryness under reduced pressure. 26.9 g of crude product are obtained which is pasted at 40 ° C for 30 minutes in 100 cm 3 of an ethyl acetate-methylene chloride mixture (1-1). The insoluble material is filtered and 5.77 g of sought product is obtained.
  • Stage B 11beta- (4-hydroxyphenyl) estra 4,9-dien-3,17-dione.
  • Stage A bromo N-butyl N-methyl acetamide.
  • Stage B 5 - [[(dimethyl (1,1-dimethylethyl) silyl] oxy] pentanol.
  • Stage C N-butyl [(5-hydroxypentyl) oxy] N-methyl acetamide.
  • Stage D [(5-bromopentyl) oxy] N-butyl N-methyl acetamide.
  • Example 1 N-butyl-5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) pentyloxy) -N-methyl-ethanethioamide.
  • Stage A N-butyl [5- [4- (3,17-dioxo estra-4,9dien-11beta-yl) phenoxy] pentyloxy] N-methyl acetamide.
  • Stage B N-butyl [5- [4- (3-hydroxy 17-oxo estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentyloxy] N-methyl acetamide.
  • Stage C N-butyl [5- [4- (3,17beta-dihydroxy estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentyloxy] N-methyl acetamide.
  • Stage D N-butyl- [5- [4- (3,17beta diacetoxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentyloxy] -N-methyl-acetamide.
  • Stage E N-butyl- [5- [4- (3,17beta-diacetoxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentoxy] -N-methyl-ethanethioamide.
  • Stage F N-butyl- [5- [4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentyloxy] -N-methyl-ethanethioamide.
  • Example 2 N-butyl-8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) -N-methyl-octanethioamide.
  • Stage A 8- [4- (3,17beta-dioxoestra-4,9-dien-11beta-yl) phenoxy] N-butyl N-methyl octanamide.
  • stage A of example 1 The procedure is carried out as in stage A of example 1 from 725 mg of product obtained in stage B of preparation A of example 1 using 0.2 cm 3 of 8-bromo N-butyl N-methyl octanamide obtained to the above preparation. After chromatography on silica (eluent: gasoline G-ethyl acetate 4-6), 540 mg of the expected product are obtained.
  • Stage B 8- [4- (3-hydroxy 17-oxo estra-1,3,5 (10) -trien-11beta-yl) phenoxy] N-butyl N-methyl octanamide.
  • stage B of Example 1 The procedure is as in stage B of Example 1 from 470 mg of the product obtained in stage A above using 260 mg palladium hydroxide on magnesium oxide. After chromatography on silica (eluent: ethyl acetate-gasoline G 1-1), 360 mg of the desired compound are obtained.
  • Stage C N-butyl-8- [4- (3,17beta-dihydroxy estra-1,3,5 (10) -trien-11beta-yl) phenoxy] N-methyl octanamide.
  • Stage D N-butyl-8- [4- (3,17beta-diacetoxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] N-methyl octanamide.
  • Stage E N-butyl-8- [4-3,17beta-acetoxy-estra-1,3,5 (10) trien11beta-yl) phenoxy] N-methyl octane thioamide.
  • Stage F N-butyl-8- [4- [3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl] phenoxy] -N-methyl-octane thioamide.
  • Example 3 11beta- monobutanedioate (4 - ((7 - ((butylmethyl amino) carbonyl) heptyl) oxy) phenyl) -3-hydroxy-estra-1,3,5 (10) -trièn-17béta-yle .
  • Example 4 11beta-butanedioate (4 - ((7 - ((butylmethylamino) carbonyl) heptyl) oxy) phenyl) -3-hydroxy-estra-1,3,5 (10) -trien-17beta-yl and sodium .
  • Example 5 8- [4- (3,17-dioxo-estra-4,9-dien-11beta-yl) phenoxy] octanoic acid.
  • Example 5 8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) -N- (2,2,3,3,4,4, 4-heptafluorobutyl) -N-methyl-octanamide.
  • Stage A 8- [4- (3,17-dioxo-estra-4,9-dien-11beta-yl) phenoxy] -N- (2,2,3,3,4,4,4-heptafluoro butyl) -N-methyloctanamide.
  • Stage B 8- [4- (3-hydroxy 17-oxo-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] -N- (2,2,3,3,4,4 , 4-heptafluorobutyl) -N-methyl octanamide.
  • Stage C 8- [4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] -N- (2,2,3,3,4,4, 4-heptafluorobutyl) -N-methyl-octanamide.
  • Example 6 2 - [(6-bromohexyl) oxy] -N-butyl-N-methylacetamide.
  • Stage A 6 - [[dimethyl (1,1dimethylethyl) silyl] oxy] hexanol.
  • stage A of preparation 3 We operate as in stage A of preparation 3, starting 8.12 g of 50% sodium hydride in oil, 20 g of 1,6-hexane diol and 25.5 g of terbutyl dimethyl chloro silane. After chromatography, 20.7 g of expected product are obtained.
  • Stage B N-butyl [(6-hydroxyhexyl) oxy] -N-methyl acetamide.
  • Stage C 2 - [(6-bromohexyl) oxy] -N-butyl-N-methylacetamide.
  • Example 6 N-butyl-2- (6- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) hexyloxy) -N-methyl-acetamide.
  • Stage A N-butyl-2- [6- [4- (3,17-dioxo-estra-4,9-dien-11beta-yl) phenoxy] hexyloxy] -N-methyl acetamide.
  • Stage B N-butyl-2- [6- [4- (3-hydroxy-17-oxo-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] hexyloxy] -N-methylacetamide.
  • stage B of Example 1 The procedure is as in stage B of Example 1 from 2.63 g of product obtained in stage A above using 2.63 g palladium hydroxide on magnesium oxide. We chromatograph the residue (2.165 g) on silica (eluent: chloride of methylene-isopropanol 94-6) and obtains 1.62 g of product expected.
  • Stage C N-butyl-2- [6-4 (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] -N-methylacetamide.
  • stage C of example 1 The operation is carried out as in stage C of example 1 from 450 mg of product obtained in stage B above using 58 mg of boron and sodium hydride. The residue is chromatographed (461 mg) on silica (eluent: methylene chloride-isopropanol 94-6) and then a second time (eluent: ethyl acetate). 274 mg of expected product is obtained.
  • Stage A dimethyl- (1,1-dimethyl ethyl) [(5-heptyn-1-yl) oxy] silane.
  • Stage B 8 - [(dimethyl- (1,1-dimethyl ethyl)] - silyloxy] -2-octynoic acid.
  • Stage C N-butyl-8 - [[dimethyl- (1,1-dimethyl ethyl)] silyloxy] N-methyl-2-octynamide.
  • Stage D N-butyl-8-hydroxy-N-methyl 2-octynamide.
  • Stage E 8-bromo N-butyl-N-methyl 2-octynamide.
  • Example 7 N-butyl-8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) -N-methyl-2-octynamide.
  • Stage A N-butyl-8- [4- (3,17-dioxo-estra-4,9-dien-11beta-yl) phenoxy] N-methyl-2-octynamide.
  • Stage B N-butyl-8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy) -N-methyl-2-octynamide.
  • Example 8 2 - [(5-bromopentyl) thio] -N-butyl-N-methyl acetamide.
  • Stage B N-butyl-2 - [(5-hydroxypentyl) thio] -N-methyl acetamide.
  • Stage C 2 - [(5-bromopentyl) thio] -N-butyl-N-methyl acetamide.
  • Example 8 N-butyl-2 ((5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) pentyl) sulfinyl) -N-methyl- acetamide.
  • Stage A N-butyl-2- [5- [4 (3,17-dioxo-estra-4,9-dien-11béta-yl) phenoxy] pentylthio] -N-methylacetamide.
  • Stage B N-butyl- [5- [4- (3-hydroxy-17-oxo-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentylthio] -N-methylacetamide.
  • Stage C N-butyl- [5- [4- (3,17beta-dihydroxy estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentylthio] N-methylacetamide.
  • stage C of Example 5 The procedure is as in stage C of Example 5, starting from 600 mg of product obtained in stage B above and 60 mg boron and sodium hydride. The expected product is obtained.
  • Stage D N-butyl-2 [[5- [4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenoxy] pentyl] sulfinyl] -N-methylacetamide.
  • Stage A (5alpha, 11beta) 3- (1,2-ethanediyl acetal cyclic) 5-hydroxy 11 - [[4- (1,1-dimethylethyl) dimethylsilyl] ethynyl-phenyl] estr-9-en-3,17 -dione.
  • Stage B 11beta- (4-ethynylphenyl) estra-4,9-dien-3,17-dione.
  • Stage C 3beta-hydroxy estra 1,3,5 (10) -trien-11beta-yl (4-ethynylphenyl) 17-one.
  • Stage D 3.17 beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] (4-ethynylphenyl) estra-1,3,5 (10) -trien-11beta-yl.
  • Stage A 3.17 beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -11beta- [4-5 [[dimethyl (11-dimethyl ethyl) silyl] oxy] 1-pentynyl] phenyl] -estra-1 , 3.5 (10) -triene.
  • Stage B 5- [4- [3,17beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -estra-1,3,5 (10) -trien-11béta-yl] phenyl] -4-pentyn -1-ol.
  • Stage A 2- (acetylthio) -N-butyl-N-methylacetamide.
  • Stage B N-methyl-N-butyl mercaptoacetamide.
  • Example 9 N-butyl-2 - ((5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenyl) pentyl) thio) -N-methyl-acetamide.
  • Stage A 2 - [[5- [4- [3,17beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -estra-1,3,5 (10) -trien-11beta-yl] phenyl] -4-pentynyl] thio] -N-butyl-N-methyl-acetamide.
  • Stage B N-butyl-2 - [[5- [4- [3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl] phenyl] -4-pentynyl] thio] - N-methyl-acetamide.
  • Stage C N-butyl-2 - ((5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenyl) pentyl) thio) -N-methylacetamide .
  • Example 10 N-butyl-4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) -N-methyl-benzenenonamide.
  • Stage A 9- [4- [3,17beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -estra-1,3,5 (10) -trien-11béta-yl] phenyl] -N-butyl -N-methyl-8-nonynamide.
  • Stage B N-butyl-4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trién-11béta-yl) N-methyl-benzenenamide.
  • Example 11 [(3-bromopropyl) oxy] -N-butyl-N-methylacetamide.
  • Stage A N-butyl [(3-hydroxypropyl) oxy] -N-methylacetamide.
  • Stage B [(3-bromopropyl) oxy] -N-butyl-N-methylacetamide.
  • Example 11 N-butyl-2 - ((5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenyl) pentyl) oxy) -N-methyl acetamide.
  • Stage A N-butyl-N-methyl-2 - [[5- [4- [3,17beta-bis [(tetrahydro 2H-2-pyrannyl) oxy] -estra-1,3,5 (10) -trien -11beta-yl] phenyl] 4-pentynyl] oxy] -acetamide.
  • stage A of example 9 The operation is carried out as in stage A of example 9, starting from 800 mg of product obtained in stage D of preparation A of example 9, 6.5 cm 3 of hexamethyl phosphorotriamide and 1.9 cm 3 of solution of butyl lithium 1M then 517 mg of product obtained in stage B of the above preparation. Extraction is carried out with methylene chloride and 5.858 g of intermediate residue are obtained. The residue is chromatographed (1.142 g) on silica (eluent: ethyl acetate-cyclohexane 1-1 to 0.1% triethylamine) and 478 mg of expected product is obtained.
  • Stage B N-butyl-2 - [[5- [4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenyl pentyl] oxy] -N-methylacetamide.
  • Example 12 sodium 6-bromo hexanoate.
  • Example 12 8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenyl) -N- (2,2,3,3,4,4, 4-heptafluorobutyl) -N-methyl-7-octynamide.
  • Stage A acid 8- [4- [3,17beta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -estra-1,3,5 (10) -trièn-11béta-yl] phenyl] -7- octynoic.
  • Stage B 8- [4- (3,17beta-dihydroxy estra-1,3,5 (10) -trien-11béta-yl) phenyl] -N- (2,2,3,3,4,4,4 -heptafluorobutyl) -N-methyl octynamide.
  • Example 13 1- (8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenyl) -1-oxo-7-octynyl) -4- ( phenylmethyl) -piperidine .
  • Stage A 3- (1,2-Ethanediyl) cyclic acetal of 11- [8-dimethyl (1,1-dimethylethyl) silyloxy] octyl 5alpha-hydroxy estr-9-en-3,17-dione.
  • Stage B 11beta- (8-hydroxy octyl) estra-4,9-dien-3,17-dione.
  • Example 14 2 - ((8- (3,17beta-dihydroxy19-nor-17alpha-pregna-1,3,5 (10) -trien-20-yn-11béta-yl) octyl) oxy) -N-methyl- N- (1-methylethyl) -acetamide.
  • Stage A [[8- (3,17-dioxo estra-4,9-dien-11béta-yl) octyl] oxy] N-methyl N- (1-methylethyl) acetamide.
  • Stage B 2 - [[8- (3-hydroxy-17-oxo-estra-1,3,5 (10) -trien-11beta-yl) octyl] oxy] -N-methyl-N- (1-methylethyl ) acetamide.
  • Stage D 2 - [[8- (3,17beta-dihydroxy 19-nor-17alpha-pregna-1,3,5 (10) -trien-20-yn-11beta-yl) octyl] oxy] -N-methyl -N- (1-methylethyl) -acetamide. methylethyl) -acetamide.
  • a potassium acetylide suspension is obtained starting from 3 cm 3 of 0.88 M solution of potassium terbutylate in tetrahydrofuran in which 5 cm 3 of tetrahydrofuran are added and then bubbled. acetylene for 15 minutes.
  • a solution of 520 mg of product obtained in stage C above is added in 5 cm 3 of tetrahydrofuran.
  • an aqueous saturated ammonium chloride solution is added, extracted with ethyl acetate, washed, dried and evaporated to dryness under reduced pressure.
  • Example 15 N-butyl-8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenylthio) -N-methyl-octanamide.
  • Stage A N-butyl- [8- [4- (3,17-dioxo-estra-4,9-dien-11beta-yl) phenylthio] -N-methyloctamide.
  • Stage B N-butyl-8- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11beta-yl) phenyl) thio) -N-methyl-octanamide.
  • stage B of Example 7 The operation is carried out as in stage B of Example 7, starting from 333 mg of product obtained in stage A above, 0.34 cm 3 of acetic anhydride and 0.17 cm 3 of acetyl bromide, then extracting with ethyl acetate.
  • the residue (335 mg) is treated with 27.5 mg of boron and sodium hydride, then 0.7 ml of 2N sodium hydroxide.
  • the residue is chromatographed (303 mg) on Lichroprep Si 60 (eluent: acetone-methylene chloride 1-9) then on Lichrosorb RP 18 (eluent: methanol-water 9-1) and 134 mg of expected product is obtained.
  • Example 16 3,17abeta-bis [(tetrahydro-2H-2-pyrannyl) oxy] -11béta- (4-ethynylphenyl) -D-homo-estra-1,3,5 (10) -triene.
  • Stage A 1,2-ethanediyl acetalcyclic 5alpha, 10alpha-epoxy 17alpha - [(tetrahydro-2H-2-pyrannyl) oxy] -D-homo estr-9 (11) en-3one.
  • Stage B 11beta- (4-ethynylphenyl) -17abeta-hydroxy-D-homo estra-4,9-dien-3one.
  • stage A of preparation A of Example 1 The operation is carried out as in stage A of preparation A of Example 1, starting with 5.7 g of the above epoxide dissolved in 46 cm 3 of tetrahydrofuran, 232 mg of copper chloride and 60 cm 3 of prepared magnesium according to stage A of preparation A of example 9 starting from 4-trimethyl ethynyl-bromobenzene described in preparation 4, which is introduced slowly, under a nitrogen atmosphere at -5 ° C / 0 ° C.
  • Stage C 3,17abeta-[4-ethynyl phenyl] -D-homo-estra-1,3,5 (10) trien-3,17abeta-diol 3,17abeta-diacetate.
  • Stage D 3.17abeta-bis [(tetrahydro-2H-2-pyrannyl) oxy] 11beta- (4-ethynylphenyl) -D-homo-estra-1,3,5 (10) -triene.
  • Example 16 N-butyl-8- (4- (3,17abeta-dihydroxy-D-homoestra-1,3,5 (10) -trien-11béta-yl) phenyl) -N-methyl-7-octynamide.
  • stage A of example 10 The procedure is carried out as in stage A of example 10, starting with 0.8 g of product obtained in stage D of the above preparation, 6.5 cm 3 of hexamethylphosphorotriamide and 1.7 cm 3 of a solution of 1.1 M butyl lithium, then add 530 mg of 6-bromo N-butyl N-methyl hexanamide prepared as in the preparation of Example 2 starting with 6-bromohexanoic acid. It is poured into a saturated solution of sodium chloride, extracted with ethyl acetate. After chromatography of the residue (3 g), 844 mg of product are obtained, the pyrannyl group of which is eliminated in 3 and 17, dissolved in 40 ml of methanol to which 8 ml of 2N hydrochloric acid are added.
  • Example 17 N-butyl-4- (3,17beta-dihydroxy-D-homoestra-1,3,5 (10) -trien-11béta-yl) -N-methyl-benzeneoctanamide.
  • Example 18 N-butyl-2- (5- (4- (3,17beta-dihydroxy-estra-1,3,5 (10) -trien-11béta-yl) phenoxy) pentyl) thio) -N-methyl ethanethioamide .
  • compositions are:
  • Tablets corresponding to the following formula were prepared: - Product of Example 2 50 mg - Excipient (talc, starch, magnesium stearate) qs for one tablet ends at 120 mg
  • Impuberous female mice aged 18 to 21 days are sacrificed, the uteri are removed and then homogenized at 0 ° C using a Potter teflon-glass in a TS buffered solution (10 mM Tris, 0.25 M sucrose, HCl pH 7.4 (1 g of tissue for 25 ml of TS) The homogenate is then ultracentrifuged (105,000 g ⁇ 90 min) at 0 ° C. Aliquots of the supernatant thus obtained are incubated at 0 ° C.
  • Tritiated bound estradiol (B) is then measured in each incubate by the carbon-dextran adsorption technique.
  • the products studied, in particular the product of example 14 have a marked affinity for estrogen receptors second time.
  • the MCF-7 lines are maintained in culture in an SVF medium (1) at 37 ° C. in a humid atmosphere containing 5% CO 2 .
  • the subconfluence cells are harvested by trypsination (0.05% trypsin, 0.02% EDTA) and then rinsed by gentle centrifugation. A sample of the cells in suspension is counted on a Malassez cell.
  • the cells resuspended in the SVF medium are seeded at the rate of 30,000 cells per well in multi-well plates (24 wells of 2.5 cm 2 ). Twenty four hours after seeding (OJ), the product to be tested is added to the medium in ethanolic solution (final ethanol concentration: 0.1%), at a concentration of 10 -12 to 10 -6 M, the control wells receiving the same ethanol concentration. The media are renewed every 48 hours. At the end of the experiment (D6), the medium is aspirated and the cells are immediately fixed with 150 microliters of methanol in order to assay the DNA.
  • the anti-proliferative activity of the products is evaluated by their ability to inhibit DNA increase.
  • DNA is assayed by a fluorimetric method using DABA (3,5 diaminobenzoic acid) (2): 150 microliters of DABA are added to each well; the plates are then incubated 45 min at 56 ° C, then 2 ml of 1N HCl are added. The fluorescence is measured using a fluorometer (length excitation wave: 408 nm, emission wavelength: 510 nm).
  • the quantity of DNA per well is evaluated relative to a standard range obtained by treating under the same conditions a calf thymus DNA standard.
  • nm concentration which inhibits the growth of MCF 7 cells (IC 50 ) by 50% was determined as indicated above:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP91402214A 1990-08-14 1991-08-09 Nouveaux 19-Nor stéroides ayant en position 11béta une chaíne carbonée comportant une fonction amide, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant Expired - Lifetime EP0471612B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9010323 1990-08-14
FR9010323A FR2665901B2 (fr) 1989-02-24 1990-08-14 Nouveaux 19-nor sterouides ayant en position 11beta une chaine carbonee comportant une fonction amide, leur preparation, leur application comme medicaments.

Publications (3)

Publication Number Publication Date
EP0471612A2 EP0471612A2 (fr) 1992-02-19
EP0471612A3 EP0471612A3 (en) 1992-05-13
EP0471612B1 true EP0471612B1 (fr) 1998-01-28

Family

ID=9399655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91402214A Expired - Lifetime EP0471612B1 (fr) 1990-08-14 1991-08-09 Nouveaux 19-Nor stéroides ayant en position 11béta une chaíne carbonée comportant une fonction amide, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Country Status (15)

Country Link
EP (1) EP0471612B1 (ko)
JP (1) JP3073803B2 (ko)
KR (1) KR920004408A (ko)
AT (1) ATE162797T1 (ko)
AU (1) AU644671B2 (ko)
CA (1) CA2049102A1 (ko)
DE (1) DE69128820T2 (ko)
DK (1) DK0471612T3 (ko)
ES (1) ES2112268T3 (ko)
GR (1) GR3026315T3 (ko)
HU (1) HUT59416A (ko)
IE (1) IE912863A1 (ko)
MX (1) MX9100647A (ko)
PT (1) PT98681B (ko)
ZA (1) ZA916420B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
KR100377280B1 (ko) * 1993-01-21 2003-07-18 메렐 파마슈티칼스 인크. 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.
US5670521A (en) * 1994-08-05 1997-09-23 Merrell Pharmaceuticals Inc. Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
DE19724187A1 (de) * 1997-06-02 1998-12-03 Schering Ag 11beta-Arylsubstituierte 14,17-Ethanoestratriene, Verfahren zur Herstellung dieser Verbindungen, sowie ihre Verwendung zur Herstellung von Arzneimitteln
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO2000026229A1 (fr) * 1998-10-29 2000-05-11 Teikoku Hormone Mfg. Co., Ltd. Derives de 2-substitues-d-homooxasteroides
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
WO2012061698A2 (en) 2010-11-05 2012-05-10 Senomyx, Inc. Compounds useful as modulators of trpm8
JP6865743B2 (ja) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384842A1 (fr) * 1989-02-24 1990-08-29 Roussel-Uclaf Nouveaux 19-nor stéroides ayant en position 11béta une chaîne carbonée comportant une fonction amide ou carbamate, leur procédé de préparation et les intermédiaires de ce procédé, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235949B1 (ko) * 1973-06-18 1978-03-17 Roussel Uclaf
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3621024C2 (de) * 1986-06-20 1999-10-28 Schering Ag 11beta-Phenylestradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384842A1 (fr) * 1989-02-24 1990-08-29 Roussel-Uclaf Nouveaux 19-nor stéroides ayant en position 11béta une chaîne carbonée comportant une fonction amide ou carbamate, leur procédé de préparation et les intermédiaires de ce procédé, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
CA2049102A1 (fr) 1992-02-15
AU644671B2 (en) 1993-12-16
ATE162797T1 (de) 1998-02-15
KR920004408A (ko) 1992-03-27
DE69128820T2 (de) 1998-06-10
EP0471612A3 (en) 1992-05-13
JP3073803B2 (ja) 2000-08-07
JPH06340688A (ja) 1994-12-13
MX9100647A (es) 1992-04-01
PT98681A (pt) 1992-07-31
EP0471612A2 (fr) 1992-02-19
GR3026315T3 (en) 1998-06-30
HUT59416A (en) 1992-05-28
DE69128820D1 (de) 1998-03-05
HU912690D0 (en) 1992-01-28
AU8242291A (en) 1992-02-20
IE912863A1 (en) 1992-02-26
ES2112268T3 (es) 1998-04-01
ZA916420B (en) 1992-10-28
PT98681B (pt) 1999-01-29
DK0471612T3 (da) 1999-02-22

Similar Documents

Publication Publication Date Title
EP0196707B1 (fr) Nouveaux 19-nor stéroides substitués en 11, en 17 et éventuellement en 2, leur préparation, leur application comme médicaments, les compositions les renfermant et les nouveaux intermédiaires obtenus
EP0188396B1 (fr) Nouveaux stéroides substitués en position 10, leur procédé et les intermédiaires de préparation, leur application comme médicaments, les compositions pharmaceutiques les contenant
EP0623140B1 (fr) Nouveaux 19-nor steroides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions
EP0262188B1 (fr) Steroides comportant un cycle spirannique en position 17, leur procede de preparation et leur utilisation
EP0384842B1 (fr) Nouveaux 19-nor stéroides ayant en position 11béta une chaîne carbonée comportant une fonction amide ou carbamate, leur procédé de préparation et les intermédiaires de ce procédé, leur application comme médicaments et les compositions pharmaceutiques les renfermant
CA1340344C (fr) Steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
CA1313653C (fr) 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
EP0305242A1 (fr) Nouveaux 17-aryle stéroides, leur procédé et intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0471612B1 (fr) Nouveaux 19-Nor stéroides ayant en position 11béta une chaíne carbonée comportant une fonction amide, leur préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0629635B1 (fr) Nouveaux 19-Nor stéroides ayant en position 11bêta une chaîne phénoxyalkylsulfonamide ou phénoxyalkylsulfonylurée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant
CA2090584C (fr) Steroides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
EP0414606B1 (fr) Nouveaux acides oméga-phénylamino alcanoiques substitués sur le noyau aromatique par un radical dérivé de 19-nor stéroides, leurs sels, leur procédé de préparation et les intermédiaires de ce procédé, leur application à titre de médicaments et les compositions les renfermant
EP0412907B1 (fr) Nouveaux esters d'acides organiques avec des alcools dérivés de 19-nor stéroides et leurs sels, leur procédé de préparation et les intermédiaires de ce procédé, leur application à titre de médicaments et les compositions les renfermant
EP0023856A2 (fr) Dérivés 17-((hydroxyméthyl)(formamido) méthylène) stéroides, leur préparation, leur application à l'introduction de la chaîne latérale hydroxyacétyle
EP0520879B1 (fr) Nouveaux stéroides 16-méthyl substitués dérivés de la pregna 1,4-diène 3,20-dione, leur préparation, leur application à la préparation de steroides 16-méthylène et nouveaux intermédiaires
FR2665901A2 (fr) Nouveaux 19-nor sterouides ayant en position 11beta une chaine carbonee comportant une fonction amide, leur preparation, leur application comme medicaments.
DE19758390A1 (de) 11ß-Halogen-7alpha-substituierte-Estratriene, Verfahren zur Herstellung pharmazeutischer Präparate, die diese 11ß-Halogen-7alpha-substituierte Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19921029

17Q First examination report despatched

Effective date: 19950123

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROUSSEL UCLAF

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 162797

Country of ref document: AT

Date of ref document: 19980215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19980129

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: HOECHST MARION ROUSSEL

REF Corresponds to:

Ref document number: 69128820

Country of ref document: DE

Date of ref document: 19980305

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2112268

Country of ref document: ES

Kind code of ref document: T3

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: HOECHST MARION ROUSSEL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
NLS Nl: assignments of ep-patents

Owner name: HOECHST MARION ROUSSEL

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20020712

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: HOECHST MARION ROUSSEL TRANSFER- AVENTIS PHARMA S.A.

NLS Nl: assignments of ep-patents

Owner name: AVENTIS PHARMA S.A.

BECA Be: change of holder's address

Owner name: S.A. *AVENTIS PHARMA20 AVENUE RAYMOND ARON, F-9216

Effective date: 20030311

BECH Be: change of holder

Owner name: S.A. *AVENTIS PHARMA

Effective date: 20030311

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20030721

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030724

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20030725

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030728

Year of fee payment: 13

Ref country code: NL

Payment date: 20030728

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20030729

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030810

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040809

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040809

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040826

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

BERE Be: lapsed

Owner name: S.A. *AVENTIS PHARMA

Effective date: 20040831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050303

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20050301

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050726

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050727

Year of fee payment: 15

Ref country code: DE

Payment date: 20050727

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050809

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060428

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060831

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060809

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060809

BERE Be: lapsed

Owner name: S.A. *AVENTIS PHARMA

Effective date: 20040831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070809